{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phosphomannomutase+2+Deficiency",
    "query": {
      "condition": "Phosphomannomutase 2 Deficiency"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 6,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T15:50:58.287Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04679389",
      "title": "Acetazolamide Efficacy in Ataxia in PMM2-CDG",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Pmm2-CDG",
        "CDG1A"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Acetazolamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "4 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2021-03-17",
      "completion_date": "2024-01-24",
      "has_results": true,
      "last_update_posted_date": "2025-03-20",
      "last_synced_at": "2026-07-22T15:50:58.287Z",
      "location_count": 3,
      "location_summary": "Rochester, Minnesota • Philadelphia, Pennsylvania • Seattle, Washington",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04679389"
    },
    {
      "nct_id": "NCT05549219",
      "title": "24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDG",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pmm2-CDG",
        "Phosphomannomutase 2 Deficiency"
      ],
      "interventions": [
        {
          "name": "GLM101",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Glycomine, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "2 Years to 65 Years"
      },
      "enrollment_count": 27,
      "start_date": "2022-11-29",
      "completion_date": "2025-11-18",
      "has_results": false,
      "last_update_posted_date": "2025-12-17",
      "last_synced_at": "2026-07-22T15:50:58.287Z",
      "location_count": 2,
      "location_summary": "Tampa, Florida • Rochester, Minnesota",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05549219"
    },
    {
      "nct_id": "NCT03173300",
      "title": "Natural History Study Protocol in PMM2-CDG (CDG-Ia)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Phosphomannomutase 2 Deficiency"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Glycomine, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 139,
      "start_date": "2018-01-08",
      "completion_date": "2026-04-09",
      "has_results": false,
      "last_update_posted_date": "2026-07-08",
      "last_synced_at": "2026-07-22T15:50:58.287Z",
      "location_count": 3,
      "location_summary": "Rochester, Minnesota • Philadelphia, Pennsylvania • Seattle, Washington",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03173300"
    },
    {
      "nct_id": "NCT04925960",
      "title": "Oral Epalrestat Therapy in Pediatric Subjects With PMM2-CDG",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pmm2-CDG",
        "Phosphomannomutase 2 Deficiency",
        "Phosphomannomutase 2 Congenital Disorder of Glycosylation",
        "Phosphomannomutase II Congenital Disorder of Glycosylation",
        "Phosphomannomutase II Deficiency"
      ],
      "interventions": [
        {
          "name": "Epalrestat",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Maggie's Pearl, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 42,
      "start_date": "2022-11-10",
      "completion_date": "2025-02-28",
      "has_results": false,
      "last_update_posted_date": "2025-09-25",
      "last_synced_at": "2026-07-22T15:50:58.287Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04925960"
    },
    {
      "nct_id": "NCT06892288",
      "title": "A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Phosphomannomutase 2 Deficiency",
        "PMM2-CDG"
      ],
      "interventions": [
        {
          "name": "GLM101 (Part A, Double-blind)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (Part A, Double-blind)",
          "type": "DRUG"
        },
        {
          "name": "GLM101 (Part B, Open-label)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Glycomine, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "4 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2025-07-09",
      "completion_date": "2027-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-02-27",
      "last_synced_at": "2026-07-22T15:50:58.287Z",
      "location_count": 4,
      "location_summary": "Minneapolis, Minnesota • New York, New York • Philadelphia, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06892288"
    },
    {
      "nct_id": "NCT06657859",
      "title": "Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pmm2-CDG",
        "Phosphomannomutase 2 Deficiency"
      ],
      "interventions": [
        {
          "name": "GLM101",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Glycomine, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2024-09-30",
      "completion_date": "2029-10",
      "has_results": false,
      "last_update_posted_date": "2026-07-14",
      "last_synced_at": "2026-07-22T15:50:58.287Z",
      "location_count": 4,
      "location_summary": "Minneapolis, Minnesota • New York, New York • Philadelphia, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06657859"
    }
  ]
}